Ocata Therapeutics - Articles and news items

Astellas to acquire Ocata Therapeutics for $379 million

Industry news / 10 November 2015 / Victoria White

Acquiring Ocata will enable Astellas to establish a presence in ophthalmology and a leading position in cell therapy…

Data from four trials support the safety and tolerability of hESC-derived retinal pigment epithelium

Industry news / 25 June 2015 /

Results of four trials provide additional evidence supporting the safety and tolerability of hESC-derived retinal pigment epithelium…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+